TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Jun 03, 2022 16:37 JST
Source:
Eisai
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
TOKYO, Jun 03, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.
Major poster presentations include the results of a subgroup analysis of the Phase III 304 clinical study on the effect of lemborexant treatment in older adults with insomnia and objectives of short sleep which is characterized by sleeping fewer than six hours (Posters #171 and #172).
"DAYVIGO continues to serve as an important asset to Eisai's neurology portfolio and we look forward to presenting the findings from several analyses at this year's SLEEP Meeting," said Ivan Cheung, Eisai Inc., Senior Vice President, President Neurology Business Group, Eisai Co., Ltd. "Insomnia can lead to daytime consequences; fatigue, difficulty concentrating and irritability,(1),(2) and causes distress or impairs functioning in social and occupational settings. Eisai remains committed to our pursuit of helping people suffering from insomnia to help address unmet medical needs."
(1) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(2) Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-S10
About Lemborexant (product name: DAYVIGO)
Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia.
For more information, visit www.eisai.com/news/2022/news202244.html.
Source: Eisai
Sectors: BioTech
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care
August 09 2022 17:09 JST
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
August 04 2022 08:25 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
August 04 2022 08:05 JST
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
July 26 2022 09:27 JST
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
July 26 2022 08:04 JST
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab
July 06 2022 09:12 JST
E.Design Insurance and Eisai Enter Into Business Alliance
June 28 2022 09:20 JST
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
June 24 2022 10:55 JST
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
June 22 2022 13:05 JST
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
June 06 2022 14:05 JST
More Press release >>
Latest Press Release
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care
Aug 09, 2022 18:09 JST
Establishment of Maritime and Ocean Digital Engineering Cooperation Program at the University of Tokyo
Aug 08, 2022 14:46 JST
Waste-to-Energy Company in Singapore Made a Wholly-Owned Subsidiary
Aug 08, 2022 14:08 JST
Rovanpera extends WRC lead with rapid home run for TOYOTA GAZOO Racing
Aug 08, 2022 11:31 JST
Team HRC Wins 43rd Suzuka 8 Hours Endurance Race
Aug 08, 2022 11:18 JST
MHI to Issue its First Transition Bond
Aug 05, 2022 17:17 JST
Mitsubishi Heavy Industries Achieves 22% YoY Increase in Order Intake and 52% YoY Increase in Net Profit in a Challenging First Quarter
Aug 05, 2022 16:40 JST
Honda Signs Agreement to Transfer Shares of Honda Lock Mfg. to MinebeaMitsumi
Aug 05, 2022 15:24 JST
MHI Group Signs Sponsorship Agreement with Thailand's Muangthong United Football Club
Aug 04, 2022 16:44 JST
Hitachi Energy Supports Huge Step in Germany's Energy Transition
Aug 04, 2022 10:02 JST
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
Aug 04, 2022 09:25 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
Aug 04, 2022 09:05 JST
Honda to Extend Power Unit Technical Support Agreement with Red Bull Power Trains to End of 2025
Aug 03, 2022 09:35 JST
NEC Visionary Week 2022 to provide insights on the future of society and business
Aug 01, 2022 13:13 JST
DENSO Announces Q1 2022 Results, Details Efforts Advancing its Pursuit of Sustainability and Safety
Jul 29, 2022 18:32 JST
Mitsubishi Power Receives Order from HK Electric for Re-provision of Gas Turbine Equipment at the Lamma Power Station
Jul 29, 2022 18:25 JST
Mazda Included in MSCI Japan ESG Select Leaders Index
Jul 29, 2022 18:17 JST
TOYOTA GAZOO Racing Ready to Defend Unbeaten Home Record
Jul 29, 2022 17:27 JST
Mazda Production and Sales Results for June 2022 and for January through June 2022
Jul 29, 2022 11:16 JST
Fujitsu and Hokuhoku Financial Group develop algorithm for efficient flood risk calculation for Task Force on Climate-related Financial Disclosures (TCFD) reporting
Jul 28, 2022 15:49 JST
More Latest Release >>